Home >Research Technology Management>Technology for Licensing


Anti-infective compounds (Tuberculosis APPN)

Intellectual Property
- Chinese Patent Issued:   ZL200980128440.2
- US Patent Issued: 8785452

Lead Inventor
Priscille Brodin, Jaeseung Kim

Stage of Development

Summary of Invention

The present invention relates to small molecule compounds, 4H-pyrido [1, 2-a] pyrimidin-4-one compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

Market Opportunity

Tuberculosis (TB) is one of the most widespread disease in the world, killing approximately 1 million every year. Current therapeutic drugs for TB takes long to cure and can be toxic. There is no cure for resistant TB. The new therapeutic drugs for multi-resistant TB will save millions of lives and bring revenue of 400 billion won every year. These compounds are the novel drug candidates to treat TB.

Patent Information

The applications for this invention went national phase of international application PCT/EP2009/004379, filed on Jun. 17, 2009; which claims the benefit of US Provisional Application No. 61/132,285, filed on Jun. 17, 2008. The applications were filed in Australia, Canada, US, Europe, Korea, Japan, China, Brazil, India and in Hong Kong. The China and US patent application were issued on Jun 4, 2014 and July 22, 2014 respectively.